The Journey of Carbamazepine
The Auto-Inducing Anticonvulsant
Carbamazepine is absorbed slowly and erratically from the gut, stabilizes neuronal sodium channels in their inactivated state to reduce repetitive firing, and uniquely induces its own metabolism via CYP3A4 upregulation — causing a progressive decline in its own plasma concentrations over weeks that requires dose re-titration and complicates virtually every co-administered drug metabolized by the liver.
Absorção
Carbamazepine is a tricyclic anticonvulsant structurally related to
imipramine that is slowly and incompletely absorbed from the GI tract, with oral bioavailability
of approximately 75-85%. However, the rate of absorption is erratic and highly variable — peak
plasma concentrations occur anywhere between 4-24 hours after a dose, reflecting the drug's poor
aqueous solubility (0.4 mg/mL) and its tendency to form polymorphic crystals in the gut. Extended-
release formulations (Carbatrol, Tegretol-XR) reduce peak-to-trough fluctuations significantly and
improve tolerability. Carbamazepine suspension has faster absorption than tablets. Food enhances
absorption. The narrow therapeutic window (4-12 µg/mL) and highly variable absorption make
therapeutic drug monitoring essential. A unique challenge: carbamazepine crystallizes from its
own suspension if mixed with certain liquid medications.
Distribuição
Carbamazepine distributes widely with a volume of distribution
of 0.8-2.0 L/kg. Plasma protein binding is approximately 75-80%, primarily to albumin. The drug
crosses the blood-brain barrier efficiently and achieves brain concentrations approximately 70-80%
of plasma concentrations — essential for anticonvulsant activity. Carbamazepine also distributes
into saliva (30-50% of plasma), breast milk (45-60% of plasma), and the placenta. Salivary
concentrations correlate well with free (unbound) plasma concentrations, enabling non-invasive
therapeutic drug monitoring. In neonates of mothers taking carbamazepine, neonatal plasma
concentrations are 50-80% of maternal, requiring observation for neonatal carbamazepine toxicity
(hypotonia, poor feeding, drowsiness) in the first days of life.
Mecanismo de Ação
Carbamazepine is a use-dependent blocker of voltage-gated sodium
channels (VGSCs), primarily Nav1.2 (SCN2A) and Nav1.6 (SCN8A) expressed in epileptogenic neurons.
It preferentially binds the inactivated state of the sodium channel (the state following action
potential depolarization), stabilizing the channel in this non-conducting state and delaying recovery
to the resting (activatable) state. This use-dependence means carbamazepine preferentially inhibits
neurons firing at high frequencies (as in seizure discharge) while sparing normal physiological
firing — a critical selectivity principle. At therapeutic concentrations, carbamazepine reduces
sustained repetitive firing without blocking single action potentials. The drug also modulates
NMDA receptors and adenosine receptors, and its active metabolite carbamazepine-10,11-epoxide
(CBZ-E) has comparable sodium channel blocking activity.
Metabolismo
Carbamazepine's metabolism is clinically transformative. It is
primarily metabolized by CYP3A4 (and to a lesser extent CYP2C8) to carbamazepine-10,11-epoxide (CBZ-E)
via epoxidation. CBZ-E is pharmacologically active (similar anticonvulsant and adverse effect profile
to the parent) and is further hydrolyzed by epoxide hydrolase (EPHX1) to the inactive trans-diol.
The critical clinical feature is autoinduction: carbamazepine is a potent inducer of CYP3A4,
CYP2C9, CYP2C19, and CYP1A2 (via PXR and CAR activation). Over 2-4 weeks of continued therapy,
CYP3A4 activity increases 2-3-fold, dramatically accelerating carbamazepine's own clearance —
the plasma half-life decreases from ~25-65 hours (initial) to ~12-17 hours (chronic). Doses must
be titrated upward to maintain therapeutic concentrations. The same induction reduces levels of
co-administered drugs: oral contraceptives, warfarin, statins, protease inhibitors, many
antiepileptics, and psychotropics.
Excreção
Carbamazepine metabolites are excreted primarily in urine (~72%)
with the remainder in feces (~28%). Less than 3% is excreted as unchanged drug in urine. The
carbamazepine-trans-diol glucuronide is the major urinary metabolite. As noted, the plasma half-life
shortens from 25-65 hours on initial dosing to 12-17 hours after 3-4 weeks due to autoinduction —
one of the most dramatic examples of autoinduction in clinical pharmacology. Steady-state is achieved
approximately 5-14 days after initiating or changing doses, with the moving target of autoinduction
requiring re-assessment of levels at 4 weeks. Renal impairment does not significantly alter
carbamazepine clearance, but hepatic impairment substantially reduces it. Hemodialysis removes
some carbamazepine but is generally not used for toxicity management.
Significância Clínica
Carbamazepine is first-line therapy for focal (partial-onset) seizures
and trigeminal neuralgia (where it is more effective than any other drug). It is also used for
bipolar disorder (mood stabilization) and glossopharyngeal neuralgia. The HLA-B*1502 allele (prevalent
in Han Chinese, Thai, and other Asian populations) is strongly associated with Stevens-Johnson
syndrome/toxic epidermal necrolysis (SJS/TEN) — FDA requires HLA-B*1502 testing before initiating
carbamazepine in these populations. HLA-A*3101 (Caucasians) is associated with maculopapular
rash. Hyponatremia (SIADH-like, due to ADH-potentiating effect) occurs in 5-40% of elderly patients.
Aplastic anemia and agranulocytosis are rare but serious hematological toxicities requiring CBC
monitoring.